This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00796289
First received: November 20, 2008
Last updated: August 26, 2015
Last verified: August 2015
  Purpose
The primary objective of this study is to determine the safety and efficacy of pulsatile GnRH delivered from a iontophoretic patch (Lutrepatch) for induction of ovulation in women with anovulatory/ oligoovulatory infertility, compared to placebo and to a reference treatment with clomiphene citrate.

Condition Intervention Phase
Infertility Drug: GnRH iontophoretic transdermal Lutrepatch Drug: clomiphene citrate Drug: placebo clomiphene citrate Drug: placebo GnRH patch Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment With Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory Infertile Females

Resource links provided by NLM:


Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Ovulation rate [ Time Frame: 30 days ]

Secondary Outcome Measures:
  • Pregnancy rate [ Time Frame: 30 days ]
  • Incidence of Ovarian Hyperstimulation Syndrome (OHSS) [ Time Frame: 30 days ]
  • Incidence of skin irritation [ Time Frame: 30 days ]

Enrollment: 350
Study Start Date: February 2009
Study Completion Date: January 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GnRH High Target Delivery
10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: GnRH iontophoretic transdermal Lutrepatch
10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
Other Names:
  • Lutrepatch
  • Gonadotropin-releasing hormone (GnRH)
Drug: placebo clomiphene citrate
oral, taken for 5 days
Experimental: GnRH Medium Target Delivery
10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: GnRH iontophoretic transdermal Lutrepatch
10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
Other Names:
  • Gonadotropin-releasing hormone (GnRH)
  • Lutrepatch
Drug: placebo clomiphene citrate
oral, taken for 5 days
Experimental: GnRH Low Target Delivery
10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: GnRH iontophoretic transdermal Lutrepatch
10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
Other Names:
  • Gonadotropin-releasing hormone (GnRH)
  • Lutrepatch
Drug: placebo clomiphene citrate
oral, taken for 5 days
Active Comparator: Clomiphene Citrate
Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
Drug: clomiphene citrate
Oral, 50 mg daily for 5 days
Other Name: various tradenames
Drug: placebo GnRH patch
Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Placebo Comparator: Placebo
Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: placebo clomiphene citrate
oral, taken for 5 days
Drug: placebo GnRH patch
Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.

  Eligibility

Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Females between the ages of 18 and 38 years
  2. Desire to become pregnant
  3. Infertile due to ovulatory dysfunction as described below:

    • Unable to conceive for at least 1 year and
    • Anovulatory (defined as 4 or fewer menstrual cycles per year) or Oligo-ovulatory (defined as menstrual cycle frequency > 45 days)

Exclusion Criteria:

  1. Requires donor oocytes or sperm
  2. Two or more failed (defined as no biochemical pregnancy achieved) gonadotropin fertility treatment cycles - if previous gonadotropin success, no more than two failed subsequent cycles
  3. Use of insulin-sensitizing drugs (e.g., Metformin) within 1 month prior to progesterone challenge
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00796289

  Show 35 Study Locations
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00796289     History of Changes
Other Study ID Numbers: 2008-03
Study First Received: November 20, 2008
Last Updated: August 26, 2015

Keywords provided by Ferring Pharmaceuticals:
anovulatory/oligoovulatory infertility

Additional relevant MeSH terms:
Infertility
Genital Diseases, Female
Fertility Agents, Female
Genital Diseases, Male
Hormones
Prolactin Release-Inhibiting Factors
Clomiphene
Enclomiphene
Zuclomiphene
Citric Acid
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Estrogen Antagonists
Hormone Antagonists
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 28, 2017